New York, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Induced Pluripotent Stem Cell (iPSC) Industry" - https://www.reportlinker.com/p05798831/?utm_source=GNW
These cells are derived from somatic cells like blood or skin cells that are genetically reprogrammed into embryonic stem cell-like state for developing an unlimited source of a diverse range of human cells for therapeutic applications. The global market is propelled by increasing demand for these cells, rising focus on researchers in the field, and their potential application in treatment of various diseases. The market growth is supplemented by rising prevalence of several chronic disorders such as diabetes, heart disease, stroke and cancer. Moreover, increasing awareness about stem cells and associated research, potential clinical applications and rising financial assistance by governments and private players are expected to contribute significantly to the market expansion. The iPSC technique is anticipated to find extensive adoption in the pharmaceutical industry for developing efficient cell sources like iPSC-derived functional cells to support drug screening and toxicity testing.
Amid the COVID-19 crisis, the global market for Induced Pluripotent Stem Cell ((iPSC) estimated at US$1.6 Billion in the year 2020, is projected to reach a revised size of US$2.3 Billion by 2026, growing at a CAGR of 6.6% over the analysis period. Vascular Cells, one of the segments analyzed in the report, is projected to record a 7.2% CAGR and reach US$835.8 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Cardiac Cells segment is readjusted to a revised 7.9% CAGR for the next 7-year period. The demand for iPSC-derived cardiac cells is attributed to diverse applications including cardiotoxicity testing, drug screening and drug validation along with metabolism studies and electrophysiology applications.
The U.S. Market is Estimated at $767.1 Million in 2021, While China is Forecast to Reach $82.4 Million by 2026
The Induced Pluripotent Stem Cell ((iPSC) market in the U.S. is estimated at US$767.1 Million in the year 2021. China, the world`s second largest economy, is forecast to reach a projected market size of US$82.4 Million by the year 2026 trailing a CAGR of 8.5% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.5 % and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR. North America leads the global market, supported by continuing advances related to iPSC technology and access to functional cells used in pre-clinical drug screening. The market growth is supplemented by increasing insights into the iPSC platform along with high throughput analysis for drug toxicity. The iPSC market in Asia-Pacific is estimated to post a fast growth due to increasing R&D projects across countries like Australia, Japan and Singapore.
Neuronal Cells Segment to Reach $336.9 Million by 2026
In the global Neuronal Cells segment, USA, Canada, Japan, China and Europe will drive the 6.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$202.9 Million in the year 2020 will reach a projected size of US$308 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$19.8 Million by the year 2026.
Select Competitors (Total 51 Featured)
- Axol Bioscience Ltd.
- Cynata Therapeutics Limited
- Evotec SE
- Fate Therapeutics, Inc.
- FUJIFILM Cellular Dynamics, Inc.
- Ncardia
- Pluricell Biotech
- REPROCELL USA, Inc.
- Sumitomo Dainippon Pharma Co., Ltd.
- Takara Bio, Inc.
- Thermo Fisher Scientific, Inc.
- ViaCyte, Inc.
Read the full report: https://www.reportlinker.com/p05798831/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Impact of Covid-19 and a Looming Global Recession
Induced Pluripotent Stem Cells (iPSCs) Market Gains from
Increasing Use in Research for COVID-19
Studies Employing iPSCs in COVID-19 Research
Stem Cells, Application Areas, and the Different Types: A Prelude
Applications of Stem Cells
Types of Stem Cells
Induced Pluripotent Stem Cell (iPSC): An Introduction
Production of iPSCs
First & Second Generation Mouse iPSCs
Human iPSCs
Key Properties of iPSCs
Transcription Factors Involved in Generation of iPSCs
Noteworthy Research & Application Areas for iPSCs
Induced Pluripotent Stem Cell ((iPSC) Market: Growth Prospects
and Outlook
Drug Development Application to Witness Considerable Growth
Technical Breakthroughs, Advances & Clinical Trials to Spur
Growth of iPSC Market
North America Dominates Global iPSC Market
Competition
Recent Market Activity
Select Innovation/Advancement
2. FOCUS ON SELECT PLAYERS
Axol Bioscience Ltd. (UK)
Cynata Therapeutics Limited (Australia)
Evotec SE (Germany)
Fate Therapeutics, Inc. (USA)
FUJIFILM Cellular Dynamics, Inc. (USA)
Ncardia (Belgium)
Pluricell Biotech (Brazil)
REPROCELL USA, Inc. (USA)
Sumitomo Dainippon Pharma Co., Ltd. (Japan)
Takara Bio, Inc. (Japan)
Thermo Fisher Scientific, Inc. (USA)
ViaCyte, Inc. (USA)
3. MARKET TRENDS & DRIVERS
Effective Research Programs Hold Key in Roll Out of Advanced
iPSC Treatments
Induced Pluripotent Stem Cells: A Giant Leap in the Therapeutic
Applications
Research Trends in Induced Pluripotent Stem Cell Space
EXHIBIT 1: Worldwide Publication of hESC and hiPSC Research
Papers for the Period 2008-2010, 2011-2013 and 2014-2016
EXHIBIT 2: Number of Original Research Papers on hESC and iPSC
Published Worldwide (2014-2016)
Concerns Related to Embryonic Stem Cells Shift the Focus onto
iPSCs
Regenerative Medicine: A Promising Application of iPSCs
Induced Pluripotent: A Potential Competitor to hESCs?
EXHIBIT 3: Global Regenerative Medicine Market Size in US$
Billion for 2019, 2021, 2023 and 2025
EXHIBIT 4: Global Stem Cell & Regenerative Medicine Market by
Product (in %) for the Year 2019
EXHIBIT 5: Global Regenerative Medicines Market by Category:
Breakdown (in %) for Biomaterials, Stem Cell Therapies and
Tissue Engineering for 2019
Pluripotent Stem Cells Hold Significance for Cardiovascular
Regenerative Medicine
EXHIBIT 6: Leading Causes of Mortality Worldwide: Number of
Deaths in Millions & % Share of Deaths by Cause for 2017
EXHIBIT 7: Leading Causes of Mortality for Low-Income and High
-Income Countries
Growing Importance of iPSCs in Personalized Drug Discovery
Persistent Advancements in Genetics Space and Subsequent Growth
in Precision Medicine Augur Well for iPSCs Market
EXHIBIT 8: Global Precision Medicine Market (In US$ Billion)
for the Years 2018, 2021 & 2024
Increasing Prevalence of Chronic Disorders Supports Growth of
iPSCs Market
EXHIBIT 9: Worldwide Cancer Incidence: Number of New Cancer
Cases Diagnosed for 2012, 2018 & 2040
EXHIBIT 10: Number of New Cancer Cases Reported (in Thousands)
by Cancer Type: 2018
EXHIBIT 11: Fatalities by Heart Conditions: Estimated
Percentage Breakdown for Cardiovascular Disease, Ischemic
Heart Disease, Stroke, and Others
EXHIBIT 12: Rising Diabetes Prevalence Presents Opportunity for
iPSCs Market: Number of Adults (20-79) with Diabetes
(in Millions) by Region for 2017 and 2045
Aging Demographics Add to the Global Burden of Chronic
Diseases, Presenting Opportunities for iPSCs Market
EXHIBIT 13: Expanding Elderly Population Worldwide: Breakdown
of Number of People Aged 65+ Years in Million by Geographic
Region for the Years 2019 and 2030
Growth in Number of Genomics Projects Propels Market Growth
EXHIBIT 14: Genomic Initiatives in Select Countries
EXHIBIT 15: New Gene-Editing Tools Spur Interest and
Investments in Genetics, Driving Lucrative Growth
Opportunities for iPSCs: Total VC Funding (In US$ Million) in
Genetics for the Years 2014, 2015, 2016, 2017 and 2018
Launch of Numerous iPSCs-Related Clinical Trials Set to Benefit
Market Growth
EXHIBIT 16: Number of Induced Pluripotent Stem Cells based
Studies by Select Condition: As on Oct 31, 2020
iPSCs-based Clinical Trial for Heart Diseases
Induced Pluripotent Stem Cells for Stroke Treatment
?Off-the-shelf? Stem Cell Treatment for Cancer Enters Clinical
Trial
iPSCs for Hematological Disorders
Market Benefits from Growing Funding for iPSCs-Related R&D
Initiatives
EXHIBIT 17: Stem Cell Research Funding in the US (in US$
Million) for the Years 2016 through 2021
Human iPSC Banks: A Review of Emerging Opportunities and Drawbacks
EXHIBIT 18: Human iPSC Banks Worldwide: An Overview
EXHIBIT 19: Cell Sources and Reprogramming Methods Used by
Select iPSC Banks
Innovations, Research Studies & Advancements in iPSCs
Key iPSC Research Breakthroughs for Regenerative Medicine
Researchers Develop Novel Oncogene-Free and Virus-Free iPSC
Production Method
Scientists Study Concerns of Genetic Mutations in iPSCs
iPSCs Hold Tremendous Potential in Transforming Research Efforts
Researchers Highlight Potential Use of iPSCs for Developing
Novel Cancer Vaccines
Scientists Use Machine Learning to Improve Reliability of iPSC
Self-Organization
STEMCELL Technologies Unveils mTeSR? Plus
Challenges and Risks Related to Pluripotent Stem Cells
A Glance at Issues Related to Reprogramming of Adult Cells to
iPSCs
A Note on Legal, Social and Ethical Considerations with iPSCs
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Induced
Pluripotent Stem Cell (iPSC) by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR
Table 2: World 7-Year Perspective for Induced Pluripotent Stem
Cell (iPSC) by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World Markets for Years 2020 & 2027
Table 3: World Current & Future Analysis for Vascular Cells by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR
Table 4: World 7-Year Perspective for Vascular Cells by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027
Table 5: World Current & Future Analysis for Cardiac Cells by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR
Table 6: World 7-Year Perspective for Cardiac Cells by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027
Table 7: World Current & Future Analysis for Neuronal Cells by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR
Table 8: World 7-Year Perspective for Neuronal Cells by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027
Table 9: World Current & Future Analysis for Liver Cells by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR
Table 10: World 7-Year Perspective for Liver Cells by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027
Table 11: World Current & Future Analysis for Immune Cells by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR
Table 12: World 7-Year Perspective for Immune Cells by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027
Table 13: World Current & Future Analysis for Other Cell Types
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR
Table 14: World 7-Year Perspective for Other Cell Types by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027
Table 15: World Current & Future Analysis for Cellular
Reprogramming by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR
Table 16: World 7-Year Perspective for Cellular Reprogramming
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027
Table 17: World Current & Future Analysis for Cell Culture by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR
Table 18: World 7-Year Perspective for Cell Culture by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027
Table 19: World Current & Future Analysis for Cell
Differentiation by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 20: World 7-Year Perspective for Cell Differentiation by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027
Table 21: World Current & Future Analysis for Cell Analysis by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR
Table 22: World 7-Year Perspective for Cell Analysis by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027
Table 23: World Current & Future Analysis for Cellular
Engineering by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR
Table 24: World 7-Year Perspective for Cellular Engineering by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027
Table 25: World Current & Future Analysis for Other Research
Methods by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR
Table 26: World 7-Year Perspective for Other Research Methods
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027
Table 27: World Current & Future Analysis for Drug Development &
Toxicology Testing by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 28: World 7-Year Perspective for Drug Development &
Toxicology Testing by Geographic Region - Percentage Breakdown
of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2020 & 2027
Table 29: World Current & Future Analysis for Academic Research
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR
Table 30: World 7-Year Perspective for Academic Research by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027
Table 31: World Current & Future Analysis for Regenerative
Medicine by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR
Table 32: World 7-Year Perspective for Regenerative Medicine by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027
Table 33: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR
Table 34: World 7-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027
III. MARKET ANALYSIS
UNITED STATES
Table 35: USA Current & Future Analysis for Induced Pluripotent
Stem Cell (iPSC) by Cell Type - Vascular Cells, Cardiac Cells,
Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 36: USA 7-Year Perspective for Induced Pluripotent Stem
Cell (iPSC) by Cell Type - Percentage Breakdown of Value Sales
for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells,
Immune Cells and Other Cell Types for the Years 2020 & 2027
Table 37: USA Current & Future Analysis for Induced Pluripotent
Stem Cell (iPSC) by Research Method - Cellular Reprogramming,
Cell Culture, Cell Differentiation, Cell Analysis, Cellular
Engineering and Other Research Methods - Independent Analysis
of Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 38: USA 7-Year Perspective for Induced Pluripotent Stem
Cell (iPSC) by Research Method - Percentage Breakdown of Value
Sales for Cellular Reprogramming, Cell Culture, Cell
Differentiation, Cell Analysis, Cellular Engineering and Other
Research Methods for the Years 2020 & 2027
Table 39: USA Current & Future Analysis for Induced Pluripotent
Stem Cell (iPSC) by Application - Drug Development & Toxicology
Testing, Academic Research, Regenerative Medicine and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 40: USA 7-Year Perspective for Induced Pluripotent Stem
Cell (iPSC) by Application - Percentage Breakdown of Value
Sales for Drug Development & Toxicology Testing, Academic
Research, Regenerative Medicine and Other Applications for the
Years 2020 & 2027
CANADA
Table 41: Canada Current & Future Analysis for Induced
Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells,
Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and
Other Cell Types - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 42: Canada 7-Year Perspective for Induced Pluripotent
Stem Cell (iPSC) by Cell Type - Percentage Breakdown of Value
Sales for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver
Cells, Immune Cells and Other Cell Types for the Years 2020 &
2027
Table 43: Canada Current & Future Analysis for Induced
Pluripotent Stem Cell (iPSC) by Research Method - Cellular
Reprogramming, Cell Culture, Cell Differentiation, Cell
Analysis, Cellular Engineering and Other Research Methods -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 44: Canada 7-Year Perspective for Induced Pluripotent
Stem Cell (iPSC) by Research Method - Percentage Breakdown of
Value Sales for Cellular Reprogramming, Cell Culture, Cell
Differentiation, Cell Analysis, Cellular Engineering and Other
Research Methods for the Years 2020 & 2027
Table 45: Canada Current & Future Analysis for Induced
Pluripotent Stem Cell (iPSC) by Application - Drug Development &
Toxicology Testing, Academic Research, Regenerative Medicine
and Other Applications - Independent Analysis of Annual Sales
in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 46: Canada 7-Year Perspective for Induced Pluripotent
Stem Cell (iPSC) by Application - Percentage Breakdown of Value
Sales for Drug Development & Toxicology Testing, Academic
Research, Regenerative Medicine and Other Applications for the
Years 2020 & 2027
JAPAN
Table 47: Japan Current & Future Analysis for Induced
Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells,
Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and
Other Cell Types - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 48: Japan 7-Year Perspective for Induced Pluripotent Stem
Cell (iPSC) by Cell Type - Percentage Breakdown of Value Sales
for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells,
Immune Cells and Other Cell Types for the Years 2020 & 2027
Table 49: Japan Current & Future Analysis for Induced
Pluripotent Stem Cell (iPSC) by Research Method - Cellular
Reprogramming, Cell Culture, Cell Differentiation, Cell
Analysis, Cellular Engineering and Other Research Methods -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 50: Japan 7-Year Perspective for Induced Pluripotent Stem
Cell (iPSC) by Research Method - Percentage Breakdown of Value
Sales for Cellular Reprogramming, Cell Culture, Cell
Differentiation, Cell Analysis, Cellular Engineering and Other
Research Methods for the Years 2020 & 2027
Table 51: Japan Current & Future Analysis for Induced
Pluripotent Stem Cell (iPSC) by Application - Drug Development &
Toxicology Testing, Academic Research, Regenerative Medicine
and Other Applications - Independent Analysis of Annual Sales
in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 52: Japan 7-Year Perspective for Induced Pluripotent Stem
Cell (iPSC) by Application - Percentage Breakdown of Value
Sales for Drug Development & Toxicology Testing, Academic
Research, Regenerative Medicine and Other Applications for the
Years 2020 & 2027
CHINA
Table 53: China Current & Future Analysis for Induced
Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells,
Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and
Other Cell Types - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 54: China 7-Year Perspective for Induced Pluripotent Stem
Cell (iPSC) by Cell Type - Percentage Breakdown of Value Sales
for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells,
Immune Cells and Other Cell Types for the Years 2020 & 2027
Table 55: China Current & Future Analysis for Induced
Pluripotent Stem Cell (iPSC) by Research Method - Cellular
Reprogramming, Cell Culture, Cell Differentiation, Cell
Analysis, Cellular Engineering and Other Research Methods -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 56: China 7-Year Perspective for Induced Pluripotent Stem
Cell (iPSC) by Research Method - Percentage Breakdown of Value
Sales for Cellular Reprogramming, Cell Culture, Cell
Differentiation, Cell Analysis, Cellular Engineering and Other
Research Methods for the Years 2020 & 2027
Table 57: China Current & Future Analysis for Induced
Pluripotent Stem Cell (iPSC) by Application - Drug Development &
Toxicology Testing, Academic Research, Regenerative Medicine
and Other Applications - Independent Analysis of Annual Sales
in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 58: China 7-Year Perspective for Induced Pluripotent Stem
Cell (iPSC) by Application - Percentage Breakdown of Value
Sales for Drug Development & Toxicology Testing, Academic
Research, Regenerative Medicine and Other Applications for the
Years 2020 & 2027
EUROPE
Table 59: Europe Current & Future Analysis for Induced
Pluripotent Stem Cell (iPSC) by Geographic Region - France,
Germany, Italy, UK and Rest of Europe Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR
Table 60: Europe 7-Year Perspective for Induced Pluripotent
Stem Cell (iPSC) by Geographic Region - Percentage Breakdown of
Value Sales for France, Germany, Italy, UK and Rest of Europe
Markets for Years 2020 & 2027
Table 61: Europe Current & Future Analysis for Induced
Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells,
Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and
Other Cell Types - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 62: Europe 7-Year Perspective for Induced Pluripotent
Stem Cell (iPSC) by Cell Type - Percentage Breakdown of Value
Sales for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver
Cells, Immune Cells and Other Cell Types for the Years 2020 &
2027
Table 63: Europe Current & Future Analysis for Induced
Pluripotent Stem Cell (iPSC) by Research Method - Cellular
Reprogramming, Cell Culture, Cell Differentiation, Cell
Analysis, Cellular Engineering and Other Research Methods -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 64: Europe 7-Year Perspective for Induced Pluripotent
Stem Cell (iPSC) by Research Method - Percentage Breakdown of
Value Sales for Cellular Reprogramming, Cell Culture, Cell
Differentiation, Cell Analysis, Cellular Engineering and Other
Research Methods for the Years 2020 & 2027
Table 65: Europe Current & Future Analysis for Induced
Pluripotent Stem Cell (iPSC) by Application - Drug Development &
Toxicology Testing, Academic Research, Regenerative Medicine
and Other Applications - Independent Analysis of Annual Sales
in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 66: Europe 7-Year Perspective for Induced Pluripotent
Stem Cell (iPSC) by Application - Percentage Breakdown of Value
Sales for Drug Development & Toxicology Testing, Academic
Research, Regenerative Medicine and Other Applications for the
Years 2020 & 2027
FRANCE
Table 67: France Current & Future Analysis for Induced
Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells,
Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and
Other Cell Types - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 68: France 7-Year Perspective for Induced Pluripotent
Stem Cell (iPSC) by Cell Type - Percentage Breakdown of Value
Sales for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver
Cells, Immune Cells and Other Cell Types for the Years 2020 &
2027
Table 69: France Current & Future Analysis for Induced
Pluripotent Stem Cell (iPSC) by Research Method - Cellular
Reprogramming, Cell Culture, Cell Differentiation, Cell
Analysis, Cellular Engineering and Other Research Methods -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 70: France 7-Year Perspective for Induced Pluripotent
Stem Cell (iPSC) by Research Method - Percentage Breakdown of
Value Sales for Cellular Reprogramming, Cell Culture, Cell
Differentiation, Cell Analysis, Cellular Engineering and Other
Research Methods for the Years 2020 & 2027
Table 71: France Current & Future Analysis for Induced
Pluripotent Stem Cell (iPSC) by Application - Drug Development &
Toxicology Testing, Academic Research, Regenerative Medicine
and Other Applications - Independent Analysis of Annual Sales
in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 72: France 7-Year Perspective for Induced Pluripotent
Stem Cell (iPSC) by Application - Percentage Breakdown of Value
Sales for Drug Development & Toxicology Testing, Academic
Research, Regenerative Medicine and Other Applications for the
Years 2020 & 2027
GERMANY
Table 73: Germany Current & Future Analysis for Induced
Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells,
Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and
Other Cell Types - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 74: Germany 7-Year Perspective for Induced Pluripotent
Stem Cell (iPSC) by Cell Type - Percentage Breakdown of Value
Sales for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver
Cells, Immune Cells and Other Cell Types for the Years 2020 &
2027
Table 75: Germany Current & Future Analysis for Induced
Pluripotent Stem Cell (iPSC) by Research Method - Cellular
Reprogramming, Cell Culture, Cell Differentiation, Cell
Analysis, Cellular Engineering and Other Research Methods -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 76: Germany 7-Year Perspective for Induced Pluripotent
Stem Cell (iPSC) by Research Method - Percentage Breakdown of
Value Sales for Cellular Reprogramming, Cell Culture, Cell
Differentiation, Cell Analysis, Cellular Engineering and Other
Research Methods for the Years 2020 & 2027
Table 77: Germany Current & Future Analysis for Induced
Pluripotent Stem Cell (iPSC) by Application - Drug Development &
Toxicology Testing, Academic Research, Regenerative Medicine
and Other Applications - Independent Analysis of Annual Sales
in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 78: Germany 7-Year Perspective for Induced Pluripotent
Stem Cell (iPSC) by Application - Percentage Breakdown of Value
Sales for Drug Development & Toxicology Testing, Academic
Research, Regenerative Medicine and Other Applications for the
Years 2020 & 2027
ITALY
Table 79: Italy Current & Future Analysis for Induced
Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells,
Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and
Other Cell Types - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 80: Italy 7-Year Perspective for Induced Pluripotent Stem
Cell (iPSC) by Cell Type - Percentage Breakdown of Value Sales
for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells,
Immune Cells and Other Cell Types for the Years 2020 & 2027
Table 81: Italy Current & Future Analysis for Induced
Pluripotent Stem Cell (iPSC) by Research Method - Cellular
Reprogramming, Cell Culture, Cell Differentiation, Cell
Analysis, Cellular Engineering and Other Research Methods -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 82: Italy 7-Year Perspective for Induced Pluripotent Stem
Cell (iPSC) by Research Method - Percentage Breakdown of Value
Sales for Cellular Reprogramming, Cell Culture, Cell
Differentiation, Cell Analysis, Cellular Engineering and Other
Research Methods for the Years 2020 & 2027
Table 83: Italy Current & Future Analysis for Induced
Pluripotent Stem Cell (iPSC) by Application - Drug Development &
Toxicology Testing, Academic Research, Regenerative Medicine
and Other Applications - Independent Analysis of Annual Sales
in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 84: Italy 7-Year Perspective for Induced Pluripotent Stem
Cell (iPSC) by Application - Percentage Breakdown of Value
Sales for Drug Development & Toxicology Testing, Academic
Research, Regenerative Medicine and Other Applications for the
Years 2020 & 2027
UNITED KINGDOM
Table 85: UK Current & Future Analysis for Induced Pluripotent
Stem Cell (iPSC) by Cell Type - Vascular Cells, Cardiac Cells,
Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 86: UK 7-Year Perspective for Induced Pluripotent Stem
Cell (iPSC) by Cell Type - Percentage Breakdown of Value Sales
for Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells,
Immune Cells and Other Cell Types for the Years 2020 & 2027
Table 87: UK Current & Future Analysis for Induced Pluripotent
Stem Cell (iPSC) by Research Method - Cellular Reprogramming,
Cell Culture, Cell Differentiation, Cell Analysis, Cellular
Engineering and Other Research Methods - Independent Analysis
of Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 88: UK 7-Year Perspective for Induced Pluripotent Stem
Cell (iPSC) by Research Method - Percentage Breakdown of Value
Sales for Cellular Reprogramming, Cell Culture, Cell
Differentiation, Cell Analysis, Cellular Engineering and Other
Research Methods for the Years 2020 & 2027
Table 89: UK Current & Future Analysis for Induced Pluripotent
Stem Cell (iPSC) by Application - Drug Development & Toxicology
Testing, Academic Research, Regenerative Medicine and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 90: UK 7-Year Perspective for Induced Pluripotent Stem
Cell (iPSC) by Application - Percentage Breakdown of Value
Sales for Drug Development & Toxicology Testing, Academic
Research, Regenerative Medicine and Other Applications for the
Years 2020 & 2027
REST OF EUROPE
Table 91: Rest of Europe Current & Future Analysis for Induced
Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells,
Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and
Other Cell Types - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 92: Rest of Europe 7-Year Perspective for Induced
Pluripotent Stem Cell (iPSC) by Cell Type - Percentage
Breakdown of Value Sales for Vascular Cells, Cardiac Cells,
Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types
for the Years 2020 & 2027
Table 93: Rest of Europe Current & Future Analysis for Induced
Pluripotent Stem Cell (iPSC) by Research Method - Cellular
Reprogramming, Cell Culture, Cell Differentiation, Cell
Analysis, Cellular Engineering and Other Research Methods -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 94: Rest of Europe 7-Year Perspective for Induced
Pluripotent Stem Cell (iPSC) by Research Method - Percentage
Breakdown of Value Sales for Cellular Reprogramming, Cell
Culture, Cell Differentiation, Cell Analysis, Cellular
Engineering and Other Research Methods for the Years 2020 &
2027
Table 95: Rest of Europe Current & Future Analysis for Induced
Pluripotent Stem Cell (iPSC) by Application - Drug Development &
Toxicology Testing, Academic Research, Regenerative Medicine
and Other Applications - Independent Analysis of Annual Sales
in US$ Thousand for the Years 2020 through 2027 and % CAGR
Table 96: Rest of Europe 7-Year Perspective for Induced
Pluripotent Stem Cell (iPSC) by Application - Percentage
Breakdown of Value Sales for Drug Development & Toxicology
Testing, Academic Research, Regenerative Medicine and Other
Applications for the Years 2020 & 2027
ASIA-PACIFIC
Table 97: Asia-Pacific Current & Future Analysis for Induced
Pluripotent Stem Cell (iPSC) by Cell Type - Vascular Cells,
Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells and
Other Cell Types - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05798831/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________